---
schema_version: "secwatch.filing_event.v1"
accession: "0001757073-22-000005"
form_type: "8-K"
ticker: "NVST"
cik: "0001757073"
company_name: "Envista Holdings Corp"
filed_at: "2022-02-09T23:59:59+00:00"
generated_at: "2026-06-27T09:39:08.647645+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Envista Q4 sales up 5.8% to $651.8M; guides FY22 core growth 6-8%, adj EBITDA margin >20%

## Summary
- Q4 net income $42.5M ($0.24 diluted EPS); adjusted EPS $0.46 vs $0.43 in Q4 2020.
- Full-year 2021 core sales growth 29%; Q4 core sales growth 6.6% on $651.8M revenue.
- 2022 guidance: core growth 6-8%, adjusted EBITDA margin >20%, barring significant COVID disruptions.
- Pending acquisition of Carestream Dental's IOS business expected to close in Q2 2022; excluded from guidance.
- Completed sale of KaVo Treatment Unit and Instrument business on Dec 31, 2021; results reflect continuing operations.

## SEC filing metadata
- accession: 0001757073-22-000005
- form_type: 8-K
- ticker: NVST
- cik: 0001757073
- company_name: Envista Holdings Corp
- filed_at: 2022-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757073/000175707322000005/0001757073-22-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757073/000175707322000005/nvst-20220209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001757073-22-000005
- JSON: https://secwatch.observer/filing/0001757073-22-000005.json
- Plain text: https://secwatch.observer/filing/0001757073-22-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.